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Strong epidemiological data indicates chemotherapy-induced gut toxicity and pain occur in parallel, 
indicating common underlying mechanisms. We have recently outlined evidence suggesting that TLR4 
signaling may contribute to both side effects. We therefore aimed to determine if genetic deletion of 
TLR4 improves chemotherapy-induced gut toxicity and pain. Forty-two female wild-type (WT) and 42 
Tlr4 null (-/-) BALB/c mice weighing between 18-25 g (10-13 weeks) received a single 270 mg/kg 
(i.p.) dose of irinotecan hydrochloride or vehicle control and were killed at 6, 24, 48, 72 and 96 h. 
Bacterial sequencing was conducted on caecal samples of control animals to determine gut microbiome 
profile. Gut toxicity was assessed using validated clinical and histopathological markers, permeability 
assays and inflammatory markers. Chemotherapy-induced pain was assessed using the validated rodent 
facial grimace criteria, as well as immunological markers of glial activation in the lumbar spinal cord. 
TLR4 deletion attenuated irinotecan-induced gut toxicity, with improvements in weight loss 
(p=0.0003) and diarrhoea (p<0.0001). Crypt apoptosis was significantly decreased in BALB/c-Tlr4-/-billy 
mice (p<0.0001) correlating with lower mucosal injury scores (p<0.005). Intestinal permeability to 
FITC-dextran (4kDa) and LPS translocation were greater in WT mice compared to BALB/c-Tlr4-/-billy 
(p=0.01 and p<0.0001, respectively). GFAP staining in the lumbar spinal cord, indicative of astrocytic 
activation, was increased at 6 and 72 h in WT mice compared to BALB/c-Tlr4-/-billy mice (p=0.008, 
p=0.01). These data indicate that TLR4 is uniquely positioned to mediate irinotecan-induced gut 
toxicity and pain, highlighting the possibility of a targetable gut/CNS axis for improved toxicity 
outcomes.  




1.0 Introduction  
Irinotecan-induced gut toxicity remains a priority concern within the field of supportive care in cancer. 
Typically used to treat a variety of solid tumours, irinotecan can cause severe diarrhoea, rectal bleeding 
and infection in patients, often resulting in dose reductions and treatment delays (1). Irinotecan-induced 
diarrhoea is clinically very significant as fluid/electrolyte imbalances can lead to renal insufficiency, 
malnutrition, and extreme dehydration. More importantly, these side effects have severe psychological 
impacts for patients and significantly effects the ability to deliver optimal treatment (2). Despite both 
its prevalence and clinical significance, the precise mechanisms that underpin gut toxicity remain 
unclear and therapeutic options for patients are limited (1).   
The broadly accepted pathophysiology of chemotherapy-induced gut toxicity (CIGT) comprises five 
continuous and overlapping phases described by Sonis (3). Although this model can be applied to most 
chemotherapeutic agents, each treatment modality has unique pathological features due to differences 
in the metabolism and pharmacokinetics of each anticancer drug. In the case of irinotecan, its unique 
enterohepatic recirculation is thought to be responsible for the high levels of intestinal toxicity. 
Irinotecan serves as the water-soluble precursor of the lipophilic metabolite SN-38, which is formed by 
carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the 
dipiperdino side chain (4). SN-38 is glucuronidated to the non-toxic SN-38 glucuronide (SN-38G) in 
the liver via the uridine-diphospho-glucuronosyl transferase (UGT1A) enzyme family, which then 
releases SN-38G into the intestine for elimination (4). However, in the intestinal lumen, bacterial -
glucuronidases regenerate SN-38 from SN-38G (5). This unique metabolic pathway not only results in 
high levels of intestinal toxicity, but also highlights the key relationship between toxicity and the gut 
microbiome (5).   
The gut microbiome has received significant attention for its role in the development of gut toxicity 
following chemotherapy, with documented changes in the balance of commensal and pathogenic 
bacteria following numerous chemotherapeutic agents (5-7). In light of these findings, the interaction 
between the gut microbiome and innate mucosal immune system has also gained interest, with 
particular emphasis on the impact of toll-like receptor (TLR) signaling (8-10). TLRs are a family of 
transmembrane protein receptors recognising a diverse range of signals on exogenous and endogenous 
substances considered to be ‘dangerous’, and hence warranting activation of the innate immune system 
for host survival (11-13). TLR4 has been most extensively characterised as it recognises, and responds 
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to, lipopolysaccharide (LPS) from gram-negative bacteria. We have shown that TLR4 is overexpressed 
in the gut during peak injury (14) and is undetectable at later time points associated with healing (15). 
Further, TLR4 is thought to induce an exacerbated innate immune response resulting in a heightened 
toxicity profile. This mechanism is particularly relevant in the setting of irinotecan-induced gut 
toxicity, as our preliminary in silico docking data indicate that SN-38 has the potential to act as a ligand 
for the TLR4/MD-2 complex.  
TLR4 has also been hypothesised to mediate chemotherapy-induced pain through central glial 
activation (9), with strong clinical evidence showing chemotherapy-induced gut toxicity is often 
paralleled by the symptom of pain (16, 17). This is suggestive of common underlying mechanisms. The 
ubiquitous involvement of the innate immune system in both chemotherapy-induced pain and gut 
toxicity therefore makes TLR4 a potentially overlooked candidate in the pathophysiology of these 
toxicities. We therefore hypothesise that TLR4-mediated signaling plays a central role in the 
development of irinotecan-induced gut toxicity and pain.  
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2.0 Materials and Methods  
2.1 Animal Model and Ethics 
The study was approved by the Animal Ethics Committee of the University of Adelaide and complied 
with National Health and Research Council (Australia) Code of Practice for Animal Care in Research 
and Training (2014). Mice were group housed in ventilated cages with three to five animals per cage. 
They were housed in approved conditions on a 12 h light/dark cycle. Food and water were provided ad 
libitum.  
2.1.1 Experimental Design  
All mice were on a BALB/c background. Forty-two female BALB/c-wild-type (WT) and BALB/c-
Tlr4-/-billy mice (ntotal=84) weighing between 18-25 g (10-13 weeks) were used. WT BALB/c mice were 
obtained from the University of Adelaide Laboratory Animal Service (SA, Australia), and BALB/c-
Tlr4-/-billy mice, back-crossed onto BALB/c for more than 10 generations, were kindly sourced from 
Professor Paul Foster from the University of Newcastle (NSW, Australia) and were originally sourced 
from Osaka, Japan (18). All BALB/c-Tlr4-/-billy mice were homozygous null mutants and hence 
expressed no detectable TLR4 mRNA or protein (personal communication MRH). Mice were treated 
with a single 270 mg/kg intraperitoneal (i.p.) dose of irinotecan hydrochloride (kindly provided by 
Pharmacia/Pfizer, Mich, USA) prepared in a sortibol/lactic acid buffer (45mg/ml sorbitol/0.9mg/ml 
lactic acid; pH 3.4; Sigma-Aldrich, NSW, Australia; D-sorbitol #S1876, lactic acid #252476), which 
was shown in pilot work to cause reproducible diarrhoea with no mortality. Control mice received the 
sorbitol/lactic acid buffer only. All mice received 0.03 mg/kg of atropine subcutaneously (s.c.) 
immediately prior to treatment to reduce the cholinergic response to irinotecan. Mice were randomly 
assigned to treatment groups and killed at 6 h, 24 h, 48 h, 72 h and 96 h. Mice were anaesthetised using 
200 mg/kg i.p. ilium sodium pentobarbital (60 mg/ml) and blood was collected from the facial vein. 
They were then killed via transcardial perfusion with cold, sterile 1 X PBS (pH 7.4) followed by 4% 
paraformaldehyde (PFA) in 0.1 M PBS (pH 7.4).  
2.1.2 Clinical assessment of gut toxicity  
All mice were monitored four times daily for the presence of diarrhoea and other clinical parameters. 
Diarrhoea was quantified (by two independent assessors) using a validated grading system where 0 = 
no diarrhoea, 1 = mild perianal staining, 2 = moderate staining covering hind legs, and 3 = severe 
 7 
staining covering hind legs and abdomen with continual anal leakage (19). Mice were weighed daily to 
track weight loss/gain. Mice were killed if they displayed ≥15% weight loss or significant distress and 
clinical deterioration, in compliance with animal ethical requirements. 
2.1.3 Facial grimace criteria 
Chemotherapy-induced pain was measured by two independent assessors, in a blinded manner, 4 times 
daily in all mice using the validated rodent facial grimace criteria (20), as previously published by our 
group (17). Briefly, the scoring method consists of five distinct criteria: orbital tightening, cheek bulge, 
nose bulge, ear position and whisker position. Each criterion was scored as 0 = absent, 1 = moderate 
and 2 = severe. Please refer to Table S1 for detailed breakdown of scoring criteria.  
2.1.4 Tissue preparation    
Gastrointestinal Tract Following anesthesia with sodium pentobarbital, mice with perfused with 
chilled, sterile 1 X PBS (pH 7.4). The entire gastrointestinal tract from pyloric sphincter to rectum was 
dissected prior to perfusion with 4% PFA and flushed with chilled 1 X PBS (pH 7.4) to remove 
intestinal contents. Both the small and large intestines were weighed immediately after resection. 
Samples (1 cm in length) of jejunum, ileum and colon were collected and (1) drop-fixed using 10% 
neutral buffered saline for processing and embedding into paraffin wax, or (2) stored in RNAlater® 
(Sigma Aldrich, NSW, Australia; #R0901) at -20oC for molecular analyses.  
Central Nervous System Mice were perfused with 4% PFA and the vertebral column dissected. 
Vertebral bodies were removed to expose the entire spinal cord. The entire spinal cord from cervical to 
lumbar regions was removed and the lumbar region prepared for further analysis (L3/L4). The mice 
were then decapitated and the brain extracted. All tissue stored in 4% PFA overnight for processing and 
embedding in paraffin wax.  
2.2 Bacterial diversity profiling  
It is well established that the gut microbiome is involved in the metabolism of irinotecan (21). To 
confirm both WT and BALB/c-Tlr4-/-billy contain similar bacterial profiles, the caecal contents of 12 
control animals (WT n=6, BALB/c-Tlr4-/-billy n=6) were aseptically collected and sent for genetic 
sequencing at the Australian Genomics Research Facility (Brisbane, Australia). 
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The sequencing details are as follows: Target: 341F-806R, Forward primer (341F): 5’-
CCTAYGGGRBGCASCAG-3’; Reverse primer (806R): 5’-GGACTACNNGGGTATCTAAT-3’; 
Read Length: 300bp 
2.2.1 Bioinformatics Method  
Paired-ends reads were assembled by aligning the forward and reverse reads using PEAR (22) (version 
0.9.5). Primers were trimmed using Seqtk (version 1.0). Trimmed sequences were processed using 
Quantitative Insights into Microbial Ecology (QIIME 1.8) (23) USEARCH (24, 25) (version 8.0.1623) 
and UPARSE software.  
Using USEARCH tools, sequences were quality filtered, full length duplicate sequences were removed 
and sorted by abundance. Singetons or unique reads in the data were discarded. Sequences were 
clustered followed by chimera filtering using the “rdp_gold” database as a reference. To obtain number 
of reads in each OTU, reads were mapped back to OTUs with a minimum identity of 97%. Using 
QUIIME, taxonomy was assigned using Greengenes database (version 13_8, Aug 2013).  
PEAR assembly read statistics were as follows: WT BALB/c control 59892 / 67175 (89.16%); 
BALB/c-Tlr4-/-billy control 57982 / 65950 (87.92%). 
2.3 Histopathological analysis  
Haematoxylin and eosin (H&E) staining was performed on 5 m sections of jejunum, ileum and colon 
cut on a rotary microtome and mounted onto glass Superfrost® microscope slides (Menzel-Gläser, 
Braunschweig, Germany). Slides were scanned using the NanoZoomer™ (Hamamatsu Photonics, 
Japan) and assessed with NanoZoomer™ Digital Pathology software view.2 (Histalim, Montpellier, 
France). The occurrence of eight histological criteria in the jejunum and ileum were examined to 
generate a total tissue injury score (26). These criteria were villous fusion, villous atrophy, disruption 
of brush border and surface enterocytes, crypt loss/architectural disruption, disruption of crypt cells, 
infiltration of polymorphonuclear cells and lymphocytes, dilation of lymphatics and capillaries, and 
oedema. In the colon, the latter six criteria were examined. Each parameter was scored as present = 1 or 
absent = 0 in a blinded fashion by two independent assessors (HRW/KRS).  
2.4 Immunohistochemistry  
2.4.1 Immunohistochemical assessment of cellular markers of apoptosis and proliferation    
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Immunohistochemistry (IHC) was carried out on 5 m sections of jejunum, ileum and colon, cut on a 
rotary microtome and mounted onto FLEX IHC microscope slides (Flex Plus Detection System, Dako, 
Denmark; #K8020). Immunohistochemical analysis was performed for caspase 3 (Abcam, Vic, 
Australia; #ab4051), a marker of apoptosis, and Ki67 (Abcam, Vic, Australia; #ab16667), a marker of 
proliferation. Changes in both parameters are validated markers for altered tissue kinetics and an 
excellent way to assess the subclinical severity of gut toxicity (27). Immunohistochemical analysis was 
performed using Dako reagents on an automated machine (AutostainerPlus™, Dako, Denmark; 
#AS480) following standard protocols supplied by the manufacturer. Briefly, sections were 
deparrafinised in histolene and rehydrated through graded ethanols before undergoing heat mediated 
antigen retrieval using an EDTA/Tris buffer (0.37 g/L EDTA, 1.21 g/L Tris; pH 9.0). Retrieval buffer 
was preheated to 65oC using the Dako PT LINK™ (pre-treatment module; Dako, Denmark; #PT101). 
Slides were immersed in the buffer and the temperature raised to 97oC for 20 min. After returning to 
65oC, slides were removed and placed in the Dako AutostainerPlus™ (Dako, Denmark; #AS480) and 
stained following manufacturer’s guidelines. Negative controls had the primary antibody omitted. 
Slides were scanned using the NanoZoomer™ (Hamamatsu Photonics, Japan) and assessed with 
NanoZoomer™ Digital Pathology software view.2 (Histalim, Montpellier, France). Apoptosis was 
quantified by counting the number of positively stained cells for 15 crypts. Data were presented as 
average positively stained cells per crypt. Ki67 data was represented as the percentage of positively 
staining cells relative to total cells in the intestinal crypts. Only well oriented, non-oblique crypts were 
included for analysis. All staining was analysed by two independent assessors (HRW/KRS). 
2.4.2 Immunohistochemical assessment of microglia and astrocyte reactivity expression markers  
Immunostaining was conducted on 5 m sections of lumbar spinal cord (L3/4), cut on a rotary 
microtome and mounted onto Superfrost® microscope slides (Menzel-Gläser, Braunschweig, 
Germany). Immunohistochemical analysis was performed for astrocytic Glial Fibrillary Acidic Protein 
(GFAP), Clone 6F2, (DakoCytomation, Dako, Denmark; #M0761) and microglial Iba-1 (Wako, 
Virginia, USA; #019-19741). Briefly, sections were dewaxed on a hot air blower and in xylene, then 
dehydrated in 100% ethanol before being quenched for endogenous peroxidase activity with 0.5% 
hydrogen peroxide in methanol for 30 min. Slides were then washed in 0.1 M PBS (pH 7.4, 2 x 3 min) 
before being subjected to heat-mediated antigen retrieval using 0.1 M citrate buffer (pH 6.0). Non-
specific binding was blocked by 3% normal horse serum (NHS; Sigma-Aldrich, NSW, Australia) for 
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30 min at room temperature. Primary antibodies were applied, using 3% NHS as the diluent, overnight 
at room temperature in a humid chamber (GFAP 2 μg/ml; Iba-1 0.1 μg/ml). Following incubation with 
the primary antibody, a secondary goat biotinylated anti-mouse/rabbit IgG (6 μg/ml) was applied to 
sections for 30 min at room temperature (Vector Laboratories, California, USA; anti-mouse #BA-9200; 
anti-rabbit #BA-1000). After a further PBS wash (2 x 3 min), slides were incubated with pierce 
streptavidin peroxidase conjugate at 2 μg/ml (ThermoFisher Scientific, Vic, Australia; #21130) for 30 
min at room temperature followed by another rinse with 0.1 M PBS. The immunocomplex was then 
visualised with precipitation of DAB (Sigma-Aldrich, NSW Australia; #D-5637) in the presence of 
hydrogen peroxide (3%). Slides were washed to remove excess DAB and lightly counterstained with 
haematoxylin, dehydrated and mounted with DePeX from histolene. Slides were scanned using the 
NanoZoomer™ (Hamamatsu Photonics, Japan) and assessed with NanoZoomer™ Digital Pathology 
software (Histalim, Montpellier, France). Staining was assessed in the dorsal column of the lumbar 
spinal cord using ImageJ 1.49 software and the validated colour deconvolution method (28).  
2.4.3 Immunohistochemical assessment of blood brain barrier permeability 
Immunohistochemical analysis was also performed on 5 m sections of brain, cut (mid-sagitally) on a 
rotary microtome and mounted onto Superfrost® microscope slides (Menzel-Gläser, Braunschweig, 
Germany). Immunostaining was performed using a rabbit polyclonal anti-human albumin antibody 
(Dako, Denmark; #A0001) as per the method described in 2.3.2. No antigen retrieval was required. 
Staining was assessed using a semi-quantitative grading system where 0 = no staining, 1 = mild 
staining with leakage localised to one region, 2 = moderate staining with two unrelated sites of leakage 
and 3 = intestine staining with 3 unrelated sites or global leakage. Staining was assessed in a blinded 
fashion by two independent assessors (HRW, JM).  
2.5 Assessment of in vivo intestinal permeability  
2.5.1 FITC-dextran assay  
Three hours prior to kill time points, mice received a 500 mg/kg dose (75 mg/ml) of 4 kDa fluorescein 
isothiocyanate (FITC)-dextran (Sigma-Aldrich, NSW, Australia; #46944) via oral gavage. Blood was 
collected from the facial vein into Multivette 600 Serum-Gel with Clotting Activator capillary tubes 
(Sarstedt, Numbretcht, Germany; #15.1670.100) and stored on ice for 30 min. Samples were 
centrifuged at 11,000 x g for 5 min at room temperature and the serum isolated. Serum samples were 
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diluted 1:3 with 1 X PBS and quantified using the BioTek Synergy™ Mx Microplate Reader (BioTek, 
Vermont, USA) and Gen5 version 2.00.18 software relative to a standard curve (range 0.0001-10 
g/ml).  
2.5.2 Serum Limulus Amebocyte Lysate (LAL) endotoxin assay  
The Limulus Amebocyte Lysate (LAL) endotoxin assay was run on serum samples isolated from blood 
collected from the facial vein into Multivette 600 Serum-Gel with Clotting Activator capillary tubes 
(Sarstedt, Numbretcht, Germany; #15.1670.100). The LAL QCL-1000TM endotoxin detection kit 
(Lonza, Basel, Switzerland; #50-647U, 50-648U) was then used to quantify serum endotoxin, as per 
manufacturer’s guidelines. Endotoxin concentration was determined relative to a linear standard curve 
(range 0.1-1 EU/ml).  
2.6 Tissue cytokine protein quantification  
2.6.1 Protein extraction  
Irinotecan causes global gastrointestinal damage, however damage is typically most severe in the ileum 
and colon. Proinflammatory cytokine expression was therefore assessed using 30 mg of ileal and 
colonic tissue samples. Intestinal tissue samples were homogenised at room temperature using the 
QIAGEN TissueLyser LT (QIAGEN, NSW, Australia) for 5 min at 50 Hz in 500 l of Radio-
Immunoprecipitation Assay (RIPA) buffer (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0) (Sigma Aldrich, NSW, Australia; #R0278) 
supplemented with Roche protease inhibitor cocktail (Sigma Aldrich, NSW, Australia; #04693116001). 
Homogenates were centrifuged at 11,000 x g for 15 min at 4oC and the supernatant isolated, aliquoted 
and stored at -80oC. Total protein concentration was quantified using the PierceTM BCA Protein Assay 
Kit (ThermoFisher Scientific, VIC, Australia; #23225). A working concentration of 1 mg/ml was used 
for cytokine analysis.  
2.6.2 Luminex multiplex cytokine assay  
Cytokine concentration was measured in individual ileal and colonic homogenates using Luminex 
xMAP technology (Milliplex Mouse Cytokine Kit, Merck Millipore, Darmstadt, Germany; 
#MPMCYTOMAG70K08) as per manufacturer’s instructions. The cytokines analysed were: IL-1, IL-
6, TNF, IL-10, IFN-, IL-2, IL-17 and MCP-1. Each 96-well plate included a 6-point standard curve 
and two quality controls provided by Merck Millipore.   
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2.7 Statistical analysis  
Data were compared using Prism version 7.0 (GraphPad® Software, San Diego, USA). A D’Agostino-
Pearson omnibus test was used to assess normality. When normality was confirmed, a two-way 
analysis of variance (ANOVA) with appropriate post hoc testing were performed to identify statistical 
significance between groups. In other cases, a Kruskal-Wallis test with Dunn’s multiple comparisons 
test and Bonferroni correction was performed. Diarrhoea data was assessed using a Chi-square test 
(29). A p-value of ˂0.05 was considered significant.   
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3.0 Results  
3.1 Bacterial diversity profiling  
Bacterial profiling showed comparable microbiome composition in both WT and BALB/c-Tlr4-/-billy 
mice (Table 1). The majority of the microbiome comprised of Fermicutes (WT 76.66 ± 5.98%; 
BALB/c-Tlr4-/-billy 71.33 ± 2.66%) and Bacteroidetes (WT 22.46 ± 6.01%; BALB/c-Tlr4-/-billy 24.34 ± 
3.00%) phyla. A two-tailed t-test with Welch’s correction showed increased expression of the 
Proteobacteria and TM7 phyla in BALB/c-Tlr4-/-billy mice (Proteobacteria: WT 0.44 ± 0.12%; BALB/c-
Tlr4-/-billy 1.93 ± 0.61%, p=0.046; TM7: WT 0.10± 0.06%; BALB/c-Tlr4-/-billy 0.55 ± 0.16%, p=0.028).  
3.2 BALB/c-Tlr4-/-billy mice have attenuated clinical manifestations of irinotecan-induced gut 
toxicity   
Irinotecan caused diarrhoea in all mice from as early as 6 h (Figure 1A and B). Diarrhoea severity was 
significantly improved in BALB/c-Tlr4-/-billy mice compared to WT (*p<0.0001). No diarrhoea was 
seen in any vehicle control animals (Figure 1C and D). Weight loss following irinotecan treatment was 
most severe at 72 h in WT (-9.96  0.98% from baseline) and Tlr4-/- mice (-5.68  0.64% from 
baseline), the weight loss in BALB/c-Tlr4-/-billy mice was significantly less than that seen in WT 
(*p<0.0001) (Figure 1E).  
3.3 BALB/c-Tlr4-/-billy mice have improved histological architecture in the small intestine  
BALB/c-Tlr4-/-billy mice treated were protected against irinotecan-induced mucosal tissue injury most 
effectively in the jejunum (Figure 2A), with improvements seen in BALB/c-Tlr4-/-billy mice compared to 
WT at 48 (*p=0.003) and 72 h (*p=0.023). Despite improvements in diarrhoea, architectural tissue 
injury remained evident at 96 h in the jejunum (Figure 2A WT #p<0.0001; BALB/c-Tlr4-/-billy 
^p=0.003) and ileum (Figure 2B WT #p<0.0001; BALB/c-Tlr4-/-billy ^p<0.0001). This late 
histopathology was not evident in the colon (Figure 2C p>0.05) suggesting colonic histopathology may 
be more indicative of diarrhoea severity. Representative images (Figure 2J) show villus blunting/fusion 
(arrow), crypt disruption (arrow head) and inflammatory infiltrate (subset panel).  
Peak apoptosis was seen at 6 h in both WT and BALB/c-Tlr4-/-billy mice (Figure 2D, E and F) with 
paralleled decreased in proliferation seen in the jejunum and ileum (Figure 2G and H). BALB/c-Tlr4-/-
billy mice had reduced apoptotic counts at 6 h in the jejunum (Figure 2D ***p<0.0001) and ileum 
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(Figure 2E *p=0.002). Representative immunostaining (Figure 2K) shows crypt caspase 3 positive cells 
in the jejunal crypts. No change was seen in proliferation between WT and BALB/c-Tlr4-/-billy mice in 
any region at any time point (p>0.05) (Figure 2G, H and I).  
3.4 TLR4-dependent signaling contributes to intestinal barrier disruption   
Serum FITC-dextran was elevated in WT mice at 24 (#p<0.0001), 48 (#p=0.0043) and 72 h (#p=0.01) 
compared to vehicle controls (Figure 3A), indicating compromised intestinal barrier function. No 
statistically significant change was seen in BALB/c-Tlr4-/-billy mice at any time point (p>0.05). At 24 h 
post-irinotecan, WT mice had significantly greater serum FITC-dextran concentrations compared to 
BALB/c-Tlr4-/-billy mice (3209.59  1020.88 ng/ml vs. 1373.97  303.56 ng/ml; *p=0.01).   
Serum endotoxin (LAL), a measure of LPS translocation, was elevated at all time points in WT mice 
treated with irinotecan (#p<0.005), with most significant peaks at 24 and 72 h (both #p<0.0001) 
(Figure 3B). Serum endotoxin was highest at 24 (^p=0.001), 48 (^p=0.003) and 96 h (^p=0.02) in 
BALB/c-Tlr4-/-billy mice treated with irinotecan compared to control. There was a significant difference 
in serum endotoxin between WT and BALB/c-Tlr4-/-billy mice at 72 h post irinotecan treatment (33.35  
2.19 EU/ml vs. 13.96  5.87 EU/ml; ***p<0.0001).  
3.5 BALB/c-Tlr4-/-billy mice exhibit a muted inflammatory response 
BALB/c-Tlr4-/-billy mice treated with irinotecan showed no statistically significant increase in IL-1β, IL-
6 or TNFα expression in the ileum or colon when compared to vehicle controls (Figure 4). There were 
significant increases in the expression of IL-1β in the ileum of WT mice treated with irinotecan 
(#p=0.04 24 h; #p=0.004 48 h). No statistically significant increase was seen in TLR4 deficient mice 
(Figure 4, p>0.05). BALB/c-Tlr4-/-billy mice lacked the IL-6 response seen in WT animals at 6 h 
(#p=0.003, *p=00002 ileum; #p=0.0004, *p=0.0005 colon) (Figure 4). WT mice also showed increased 
ileal expression of TNFα (#p=0.01) 24 h after treatment with irinotecan and this was significantly 
elevated relative to treated BALB/c-Tlr4-/-billy mice (*p=0.02). No change was seen in IL-10.  
3.6 Irinotecan-induced pain is associated with TLR4-dependent astrocytic GFAP expression 
Facial grimace criteria peaked at 6 h in both treated animals groups, reducing steadily for the remainder 
of the experimental time-course (Figure 5A). From 6 to 72 h, BALB/c-Tlr4-/-billy mice had reduced 
facial grimace criteria compared to WT mice (***p<0.0001). Elevated GFAP staining, indicative of 
astrocyte activation, was seen at 6 h in WT animals compared to controls (#p=0.004) (Figure 5B). 
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GFAP staining was significantly greater in WT compared to BALB/c-Tlr4-/-billy mice at 6 (*p=0.008) 
and 72 h (*p=0.01). No change was seen in Iba-1 staining in any animals (Figure 5C; p>0.05). 
Representative images (Figure 5D) support activation of astrocytes with obvious changes in phenotype 
6 h after irinotecan in WT mice.  
3.7 Irinotecan increases blood brain barrier permeability to albumin  
Elevated albumin staining was seen in WT (#p=0.0001) and BALB/c-Tlr4-/-billy mice (^p=0.03) at 24 h, 
and in WT mice at 48 and 72 h (#p=0.006 and #p=0.03, respectively) (Figure 6A), although there was 
no difference between WT and BALB/c-Tlr4-/-billy mice (p>0.05). Both parenchymal (Figure 6C) and 
perivascular (Figure 6D) albumin was evident in WT and BALB/c-Tlr4-/-billy mice treated with 
irinotecan, with minimal leakage in control animals (Figure 6B).   
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4.0 Discussion  
TLR4 has been hypothesised to play a key role in the development of both chemotherapy-induced gut 
toxicity and pain (9, 17).  Results from the current study support this newly proposed hypothesis, 
highlighting significant improvements in symptomatic parameters of gut toxicity and histopathological 
markers in BALB/c-Tlr4-/-billy mice treated with irinotecan. This study is also the first to show 
paralleled improvements in in vivo pain markers and central glial reactivity following irinotecan.  
The gut microbiota is critical in regulating the severity of gut toxicity, with increased levels of LPS-
producing, gram-negative bacteria correlating with diarrhoea severity (5, 30). Comparable levels of 
major phylogenies (fermicutes, bacteroidetes) were seen in WT and BALB/c-Tlr4-/-billy mice at baseline. 
However, small variations were seen in two relatively low abundance microbes. These differences seen 
in the composition of the gut microbiome in WT and BALB/c-Tlr4-/-billy mice are not surprising given 
the wealth of emerging evidence indicating that both genetic and environment factors, such as breeding 
rooms//facilities, weigh significantly on the composition of the gut microbiome (31). 
At baseline, TLR4 knockout mice exhibited higher levels of the TM7 bacterial phyla. Little is known 
about this bacterial phylogeny, however it has been suggested to contribute to inflammatory 
pathologies within the gastrointestinal tract (32). More importantly, BALB/c-Tlr4-/-billy mice had 
elevated levels of -glucuronidase-producing proteobacteria, likely increasing the rate of SN-38 
reactivation, and thus worsened gut toxicity. Despite this predisposition, BALB/c-Tlr4-/-billy mice 
showed improvements in both the duration and severity of symptoms compared to WT mice. This 
finding compliments recent research showing that germ-free mice experienced less severe irinotecan-
induced gut toxicity compared to conventional mice (33). Most importantly, the germ-free mice also 
had higher levels of unbound SN-38 and higher -glucuronidases activity. Comparatively, depletion of 
the gut microbiome with oral antibiotics has shown to be effective in reducing irinotecan-induced 
diarrhoea (34). It is now essential to determine if these improvements are the results of reduced 
microbial metabolism and SN-38 reactivation, or the result of reduced TLR4-mediated signaling. 
Determination of which factor contributes more significantly to clinical outcomes would therefore 
better direct therapeutic research efforts.  
Extensive literature exists showing the protective effect of TLR4 deletion in an inflammatory setting, 
however this appears to be limited to only acute insults, with TLR4 deficiency exacerbating chronic 
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inflammatory diseases (35). For example, significant improvements in acute inflammation have been 
shown in the absence of TLR4 and MyD88, a downstream signaling molecule of TLR, following acute 
infection with Citrobacter rodentium (35). Similar results have also been demonstrated in 
methotrexate-induced gut toxicity, with MD-2 (TLR4 accessory protein) deletion improving clinical 
and histological parameters of toxicity (36). Importantly, this study showed that TLR4 and TLR2 
appear to have opposing roles, with both genetic deletion and pharmacological inhibition of TLR2 
worsening methotrexate-induced damage (36). It appears that TLR2 has paradoxical roles in 
chemotherapy-induced gut toxicity, with improvements seen in Tlr2-/- mice treated with irinotecan. 
This study also showed that Myd88-/- mice were also protected from developing severe irinotecan-
induced gut toxicity, reiterating the importance of TLR4-dependent signaling (36). Despite support for 
TLR4 deletion providing protection against chemotherapy-induced gut toxicity, this does not appear to 
be the case for acute and chronic colitis, with Tlr4-/- mice more susceptible to ulceration and bleeding 
(35). Although the unique mechanisms to each effect are not understood, these data do imply 
ambivalent roles for TLR4 in different inflammatory-based pathologies in the gastrointestinal tract.  
It is well established that irinotecan-induced gut toxicity occurs through apoptosis of crypt epithelial 
cells through the gastrointestinal tract and consequently apoptosis is an established marker of toxicity 
severity (27). Our results showed significantly decreased levels of apoptosis in the jejunum and ileum 
of irinotecan-treated BALB/c-Tlr4-/-billy mice. This supports recent research suggesting that TLR4 
signaling contributes to intestinal stem cell apoptosis through endoplasmic reticular stress-related 
mechanisms (37). We also saw levels of proliferation inversely parallel these changes in cellular 
dynamics. This is of great clinical significance as apoptosis is one of the initial steps in the cascade of 
biological events that results in the development of gut toxicity. If TLR4 deletion is able to profoundly 
impact such an early mediator of toxicity, it provides an excellent opportunity to intervene prior to 
architectural tissue damage, inflammation and bacterial translocation.  
In this study, increased FITC-dextran and endotoxin permeability were seen in irinotecan-treated WT 
mice, indicative of altered intestinal barrier function. Importantly, Tlr4-/- maintained intestinal barrier 
function with no significant changes in FITC-dextran permeability and decreased LPS translocation. 
Surprisingly, BALB/c-Tlr4-/-billy mice only showed mild improvements in serum endotoxin compared to 
WT mice and this did not appear to reflect the differences in intestinal damage. The failure to show 
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differences at most time points in this study could be explained by evidence suggesting that TLR4 on 
hepatocytes is required for complete endotoxin clearance (38).  
Reducing bacterial translocation has profound implications for systemic inflammatory responses and 
the exacerbation of direct mucosal cytotoxicity. Highlighting this pathobiological mechanism, 
BALB/c-Tlr4-/-billy mice, displayed less severe intestinal inflammation compared to WT mice. The most 
significant difference was seen for IL-6, in which BALB/c-Tlr4-/-billy mice showed no increase after 
treatment, supporting the idea that TLR4-dependent NFB activation is required for the release of IL-6 
from macrophages (39). Stunted IL-6 production has also been seen in MyD88 deficient mice (40) and 
Tlr4-/- macrophages (41). 
The current study also identified, for the first time, disruption of the blood brain barrier in animals 
treated with irinotecan. Blood brain barrier disruption has been hypothesised to contribute to the 
development of ‘chemobrain’ and cognitive impairment seen following chemotherapy, allowing 
cytotoxic agents direct access to the CNS (42). It has also been suggested uncontrolled blood brain 
barrier transit may potentiate the ability of peripheral inflammation to influence central pain signaling. 
It is becoming increasingly recognised that TLR4, expressed on centrally located glia, is able to 
recognise and respond to peripherally derived LPS and inflammatory mediators (9). We have shown 
translocation of LPS to systemic circulation following chemotherapy treatment, reflecting the swing 
towards a gram-negative, pathogenic gut microbiome profile following chemotherapy. Despite this, we 
saw no association serum LPS, glial activation and pain. Instead, astrocytic activation appeared to 
occur bimodally, with increases in GFAP staining seen at 6 and 72 h. This suggests that cellular events 
associated with apoptosis (which peaks at 6 h), or inflammation may be more important in TLR4-
mediated glial activation. This concept is particularly compelling when looking at recent research by Ji 
et al., (2013) who reported significant astrocytic hypertrophy and activation in the dorsal horn of 
vincristine-treated rats with mechanical allodynia (43). Treatment with pentoxifylline, an anti-
inflammatory agent, attenuated astrocytic reactivity and mechanical allodynia. Astrocytic reactivity has 
also been identified in the lumbar spinal cord of rats receiving oxaliplatin treatment, providing 
evidence linking peripheral inflammation and central gliosis. It is now critical to determine if the 
irinotecan-induced gut toxicity and pain are independent, yet simultaneously occurring events that are 
both governed by TLR4, or if there is a true directional mechanism linking one to the other.  
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Data from the current study have clearly highlighted the involvement of TLR4 in the development of 
irinotecan-induced gut toxicity and pain, provide a unique opportunity to simultaneously treat 
irinotecan-induced toxicities. In all cases of TLR4-targeted therapeutic options, the effect on both the 
efficacy of the anti-cancer therapy and overall tumour kinetics are paramount. This is particularly the 
case when targeting TLR4, as recent evidence now suggests that it may play critical roles in tumour 
growth. For example, an Apetoh et al. (2007) showed that TLR4 deficient animals had increased 
tumour growth under normal, conditions and in response to doxorubicin (44). TLR4 inhibition has also 
been implicated in tumour regression, with several studies now showing that numerous cancer cell lines 
(e.g. SW260 [colon], CRC-526 [breast], PC3 [prostate]) overexpress TLR4 and that LPS stimulates 
their growth (45-47). In addition, although not assessed in the current study, future work will need to 
clarify the role of TLR4 in normal gastrointestinal motility patterns given recent research implicating 
TLR4 in altered motility patterns following opioid treatment (48, 49).  
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5.0 Conclusions  
Given the ubiquitous involvement of the innate immune system, particularly TLR4, in gut homeostasis 
and central pain signaling, it presents as a potentially overlooked candidate in the treatment of 
chemotherapy-induced gut toxicity and pain. Our research has demonstrated that TLR4 is pivotal in the 
development of both toxicities. This research not only improves our understanding of the underlying 
mechanisms involved, but also reveals a promising opportunity to intervene in the complex 
pathophysiology of these dose-limiting side effects of chemotherapy. Research efforts must now be 
targeted at tailoring methods of inhibiting TLR4, keeping in mind the potential effects on tumour 
burden and gastrointestinal function.   
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8.0 Tables  
 
Table 1: Mean percentage of each caecal bacterial phyla in vehicle-treated WT and Tlr4-/- null mice.  
Phylum WT Tlr4
-/-
 p-value  
Bacteroidetes 22.45±6.00 24.34±3.01 0.79 
Firmicutes 76.65±5.98 71.33±2.66 0.46 
Proteobacteria 0.43±0.12 1.93±0.61 *0.05 
TM7 0.10±0.06 0.56±0.16 *0.03 
Actinobacteria 0.25±0.09 0.65±0.19 0.09 
Cyanobacteria 0.02±0.01 0.10±0.04 0.08 
Acidobacteria 0.002±0.001 0.0004±0.0003 0.26 
Verrucomicrobia 0.0005±0.0005 0.13±0.11 0.27 
Deferribacteres 0.005±0.003 0.0006±0.0003 0.23 
Tenericutes 0.02±0.02 0.92±0.53 0.13 
Chloroflexi 0.02±0.005 0.01±0.01 0.58 
Nitrospirae 0.003±0.001 0.003±0.002 0.70 
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9.0 Figure legends  
Figure 1 Tlr4-/- attenuates symptomatic parameters of gut toxicity: diarrhoea and weight loss. 
Diarrhoea profiles shown for WT BALB/c mice (A) and BALB/c-Tlr4-/-billy mice (B) treated with 270 
mg/kg of irinotecan, as well as vehicle treated controls (C, D). Diarrhoea data is expressed as the 
percentage of total animals (per time point) with a particular grade of diarrhoea. Data was analysed 
using a Chi-Squared test. Diarrhoea was most significant at 24 h post-treatment in both treatment 
groups. Diarrhoea was significantly improved in BALB/c-Tlr4-/-billy mice compared to WT 
(***p<0.0001). Panel E shows weight loss over the 96 h time course. Data displayed as percentage 
weight change from baseline (0 h). A Kruskal-wallis with post hoc testing was performed to identify 
statistical significance.  BALB/c-Tlr4-/-billy mice had significantly less body weight loss at 24 h 
(**p=0.003), 48 h, 72 h and 96 h (***p<0.0001).  
Figure 2 Histopathological parameters in jejunum, ileum and colon of WT and BALB/c-Tlr4-/-billy 
mice. There were significant increases in tissue injury scores in WT and BALB/c-Tlr4-/-billy mice in the 
jejunum (A), ileum (B) and colon (C); # denotes a change from baseline in WT mice, where p<0.05; ^ 
denotes a change from baseline in BALB/c-Tlr4-/-billy mice, where p<0.05. Data presented as 
interquartile rangemix/max. TLR4 deletion reduced the severity of jejunal and ileal tissue damage (A 
*p=0.003 48 h, *p=0.023 72 h); B *p=0.005 96 h). Apoptosis was increased in the jejunum (D), ileum 
(E) and colon (F) in all treated animals (p<0.05). TLR4 deletion attenuated apoptosis in the jejunum 
and ileum (D ***p<0.0001 6 h; E *p=0.0023 6 h). Decreased small intestinal proliferation was noted at 
6 h in all animals treated with irinotecan (G and H), however no differences were seen between WT 
and BALB/c-Tlr4-/-billy mice. No change was seen in the colon (I). Representative histological (J) and 
caspases-3 immunostaining (K) show clear jejunal tissue injury at 48 h characterised by crypt ablation 
(arrow head), villous blunting/fusion (arrow), inflammatory infiltrate (subset panel) and crypt apoptosis 
at 6 h (brown staining [arrow]; Panel K). Scale bars show 30 m. Original magnification 40 x.  
Figure 3 Ex vivo markers of barrier permeability, serum 4 kDa FITC-dextran (A) and serum 
endotoxin (B). FITC-dextran was administered as a 500 mg/kg dose, via oral gavage, 3 h prior to kill 
time point. Serum endotoxin was assessed using the Serum Limulus Amebocyte Lysate (LAL) 
endotoxin assay. Data is expressed as meanSEM and was analysed using a two-way ANOVA with 
Tukey’s post hoc. Both markers of barrier disruption show elevations following treatment with 
irinotecan (# denotes a change from baseline in WT mice; ^ denotes a change from baseline in 
BALB/c-Tlr4-/-billy mice, where p<0.05). Maximum FITC-dextran permeability coincides with peak 
diarrhoea in WT animals (24 h). At this time point, TLR4 deletion decreased serum FITC-dextran 
levels (*p=0.0104) compared to WT. Serum endotoxin, indicative of LPS translocation, was reduced in 
BALB/c-Tlr4-/-billy mice at 72 h compared to WT mice treated with irinotecan (***p=0.0001).  
Figure 4 Cytokine expression in the ileum and colon. Cytokine expression was assessed using 
Luminex xMAP technology. Data expression as mean±SEM (pg/ml). A two-way ANOVA with 
Tukey’s post hoc was performed to identify statistical significance. IL-1β expression increased in the 
ileum of WT animals treated with irinotecan compared to control (#p=0.0394 24 h; #p=0.0036 48 h). 
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Only a significant decrease was seen in BALB/c-Tlr4-/-billy mice (# denotes a change from baseline in 
WT mice; ^ denotes a change from baseline in BALB/c-Tlr4-/-billy mice, where p<0.05). BALB/c-Tlr4-/-
billy mice lacked an IL-6 response at 6 h, with significantly lower expression compared to WT mice 
(**p=0.0002 ileum; **p=0.0005 colon). TNFα expression peaked at 24 h in the ileum of WT mice 
treated with irinotecan (#p=0.0113). This was significantly elevated relative to BALB/c-Tlr4-/-billy mice 
(*p=0.0166), which showed no elevation in TNFα (p>0.05). No change was seen in the anti-
inflammatory cytokine, IL-10.  
Figure 5 Facial grimace criteria (A-D), GFAP staining (marker of astrocytic reactivity; E,G) and 
Iba-1 staining (marker of microglial reactivity; F) following irinotecan treatment. Facial grimace 
scores were assessed four times daily using the facial grimace criteria. Most significant facial pain was 
seen at 6 h following treatment with irinotecan (A,B). Tlr4-/- mice had lower facial pain scores at all 
time points (***p<0.0001 6-72 h; *p=0.0072 96 h). GFAP and Iba-1 immunostaining was assessed in 
the dorsal column of the lumbar spinal cord. Increased astrocytic activation (GFAP) was seen in treated 
WT mice at 6 h compared to controls (E; #p=0.0041). This was not evident in BALB/c-Tlr4-/-billy mice 
(p>0.05). Irinotecan-treated WT mice showed increased GFAP staining compared to BALB/c-Tlr4-/-billy 
mice at 6 h (*p=0.008) and 72 h (*p=0.012). No change was seen in microglial activity (Iba-1) across 
the full time course in both WT and Tlr4-/- mice (F; p>0.05). Data presented as meanSEM. Panel G 
shows representative images of GFAP staining in vehicle control WT mice and 6 h after irinotecan. 
Scale bars show 50 m or 10 m for representative images and subset panels, respectively. Original 
magnification 40 x. WT mice treated with irinotecan displayed morphological changes in astrocyte 
phenotype (somatic hypertrophy, thickened and ramified processes) indicative of an activated state.  
Figure 6 Irinotecan causes blood brain barrier dysfunction. Staining was analysed using a semi-
quantitative 0-3 grading system and represented as interquartile rangemix/max. A Kruskal-Wallis 
with post hoc testing was performed to identify statistical significance in non-parametric data. Scale 
bars show 20 m, 100 m and 50 m for panels B, C and D, respectively. Original magnification 40 x. 
Albumin staining, indicative of increased blood brain barrier transit, was elevated compared to 
untreated controls at 24 h (#p<0.0001), 48 h (#p=0.0063) and 72 h (#p=0.0325) in WT mice; this was 
only seen at 24 h (^p=0.0325) in BALB/c-Tlr4-/-billy mice. No differences were seen between WT and 
BALB/c-Tlr4-/-billy mice (p>0.05). Qualitative assessment showed that albumin leakage was not limited 
to a particular brain region, but affected the vasculature globally with both parenchymal (C) and 
perivascular (D) albumin staining noted. Minimal leakage was observed in control animals (B).  
